Related Experiment Video
Updated: Apr 5, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
21.3K
Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy
David Gibbes Miller1, Y Helen Zhang1, Maria Thor2
1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract:
We evaluated acute toxicity and disease control in 42 patients receiving thoracic radiotherapy with concurrent KRAS G12C inhibitors. Toxicity included 13 grade 2 events (31%) and one grade 3 pneumonitis. There were no significant differences in toxicity between patients who held versus continued inhibitors during radiotherapy. The estimated cumulative incidence of local failure at 6 months was 5%.
